Session Details

S017 The 2025 Debates: Controversies in Dermatology

Fri, Mar 7, 1:00 PM - 4:00 PM
Valencia Ballroom B
3 CME Available Symposium
View Map

DESCRIPTION

Open admission to eligible categories, no tuition or ticket

Evidence-based medicine is the conscientious and judicious use of the strongest current data in making decisions on how we care for our patients. Advances in technology, development of new therapies, and acquisition of new data challenge our best practices and may at the same time stimulate controversy. This session is designed for interactive discussion and critical thinking regarding some of the emerging issues that we are actively encountering in this current day.

LEARNING OBJECTIVES

1.

Critically evaluate key issues and challenges in deploying molecular testing for the determination of melanoma risk and outcomes.

2.

Define and recognize the current opportunities and challenges with developing and using Artificial Intelligence applications in dermatology.

3.

Critically evaluate the key issues and challenges associated with melanoma (over)diagnosis and skin cancer screening.

SCHEDULE

6:00 PM

Introduction

Kenneth Y. Tsai, MD, PhD, FAAD

6:05 PM

Applications of Artificial Intelligence in Dermatology - Part 1

Yevgeniy Semenov, MD, MS, FAAD

6:25 PM

Applications of Artificial Intelligence in Dermatology - Part 2

Shannon Wongvibulsin, MD, PhD

6:45 PM

Open Discussion

Yevgeniy Semenov, MD, MS, FAAD, Shannon Wongvibulsin, MD, PhD

7:05 PM

The Clinical Utility of Molecular Testing in Melanoma and Keratinocyte Carcinomas - Part 1

Emily Y. Chu, MD, PhD, FAAD

7:25 PM

The Clinical Utility of Molecular Testing in Melanoma and Keratinocyte Carcinomas - Part 2

David Cotter, MD, PhD, FAAD

7:45 PM

Open Discussion

Emily Y. Chu, MD, PhD, FAAD, David Cotter, MD, PhD, FAAD

8:05 PM

The Challenges of Melanoma (Over)Diagnosis and Screening - Part 1

Adewole Shomari Adamson, MD, MPP, FAAD

8:25 PM

The Challenges of Melanoma (Over)Diagnosis and Screening - Part 2

David Polsky, MD, PhD, FAAD

8:45 PM

Open Discussion

Adewole Shomari Adamson, MD, MPP, FAAD, David Polsky, MD, PhD, FAAD

SPEAKERS

Adewole Shomari Adamson, MD, MPP, FAAD

Adewole Shomari Adamson, MD, MPP, FAAD

Emily Y. Chu, MD, PhD, FAAD

Emily Y. Chu, MD, PhD, FAAD

David Cotter, MD, PhD, FAAD

David Cotter, MD, PhD, FAAD

David Polsky, MD, PhD, FAAD

David Polsky, MD, PhD, FAAD

Yevgeniy Semenov, MD, MS, FAAD

Yevgeniy Semenov, MD, MS, FAAD

Kenneth Y. Tsai, MD, PhD, FAAD

Kenneth Y. Tsai, MD, PhD, FAAD

Shannon Wongvibulsin, MD, PhD

Shannon Wongvibulsin, MD, PhD

SPEAKER DISCLOSURES

Adewole Shomari Adamson, MD, MPP, FAAD

No financial relationships exist with ineligible companies.

Emily Y. Chu, MD, PhD, FAAD

No financial relationships exist with ineligible companies.

David Cotter, MD, PhD, FAAD

AbbVie – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Investigator(Fees), Speaker(Honoraria); Arcutis Biotherapeutics – Speaker(Honoraria); Boehringer Ingelheim – Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Bristol Myers Squibb – Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Castle Biosciences – Investigator(Fees), Speaker(Honoraria), Speaker/Faculty Education(Honoraria); Dermavant Sciences, Inc. – Consultant (1099 relationship)(Honoraria); DermTech Inc. – Speaker(Honoraria); Galderma – Speaker(Honoraria); janssen – Advisory Board(Honoraria); Leo Pharma – Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Novartis – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria); Pfizer Inc. – Advisory Board(Honoraria); Sanofi/Regeneron – Speaker(Honoraria); UCB – Advisory Board(Honoraria);

David Polsky, MD, PhD, FAAD

BMS – Independent Contractor(Grants/Research Funding); Medscape – Speaker(Honoraria); MoleSafe, Inc. – Other(Fees); Novartis – Independent Contractor(Grants/Research Funding); Viela Bio – Advisory Board(Stock);

Yevgeniy Semenov, MD, MS, FAAD

Bristol Myers Squibb – Consultant (1099 relationship)(Honoraria); Journal of the American Academy of Dermatology – Other(Salary); Pfizer Inc. – Consultant (1099 relationship)(Honoraria); Regeneron – Advisory Board(Honoraria); Sanofi – Advisory Board(Honoraria);

Kenneth Y. Tsai, MD, PhD, FAAD

3CC - Third Culture Capital – Stockholder(No Compensation Received); Altos Labs – Consultant (1099 relationship)(Fees); APIS Assay Technologies – Independent Contractor(Grants/Research Funding); DX Biosciences, Inc – Consultant(Stock Options); Incyte Corporation – Investigator(Grants/Research Funding); NFlection Therapeutics, Inc – Consultant(Fees); UpToDate – Independent Contractor(Fees); Verrica Pharmaceuticals Inc – Independent Contractor(Fees);

Shannon Wongvibulsin, MD, PhD

Sanofi/Regeneron – Advisory Board(Honoraria); VisualDx – Consultant (1099 relationship)(Honoraria);